ALAD Knockout A-549 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the A-549 human lung adenocarcinoma cell line, featuring targeted disruption of the ALAD gene. This product provides a heterogeneous pool of knockout cells, enabling robust functional studies without single-cell cloning artifacts, and is suitable for experiments requiring a representative loss-of-function model for heme biosynthesis research.
The A-549 host cell line originates from a lung carcinoma and is widely utilized as an epithelial model for pulmonary adenocarcinoma, drug metabolism, and toxicology. Its adherent epithelial morphology and well-characterized growth properties make it an ideal platform for investigating heme-dependent processes in a non-erythroid context, where heme synthesis supports mitochondrial respiration and drug-metabolizing cytochrome P450 enzymes.
The ALAD gene encodes delta-aminolevulinic acid dehydratase, which catalyzes the zinc-dependent asymmetric condensation of two 5-aminolevulinic acid molecules to form porphobilinogen, the second committed step of the heme biosynthetic pathway. This reaction is sensitive to inhibition by lead, linking ALAD function to acute lead poisoning susceptibility. Downstream, porphobilinogen is sequentially processed by PBGD, UROS, UROD, CPOX, PPOX, and FECH to produce heme, which serves as a critical cofactor for hemoproteins including cytochrome c, catalase, and peroxidases. In erythroid cells, ALAD is transcriptionally regulated by GATA1 and KLF1; however, in A-549 cells, its expression is constitutive, allowing focused dissection of heme synthesis independent of erythroid differentiation signals.
Disruption of ALAD in A-549 cells ablates the production of porphobilinogen, leading to a profound block in heme biosynthesis. This knockout model consequently impairs mitochondrial electron transport chain function, as heme is essential for cytochrome c assembly, and disrupts the activity of numerous heme-dependent enzymes such as cytochrome P450 oxidases. The polyclonal nature of the knockout population maintains genetic diversity, mimicking the heterogeneity of tumor cell populations and providing a realistic system for studying metabolic vulnerabilities in lung adenocarcinoma cells devoid of heme synthesis.
Researchers can leverage this ALAD knockout polyclonal cell pool for a broad array of applications, including quantification of porphobilinogen accumulation to confirm pathway blockade, measurement of residual ALAD enzyme activity, profiling of heme levels via biochemical assays, and Western blot analysis of heme pathway enzymes. Functional studies such as mitochondrial respiration assays (Seahorse analysis) and lead sensitivity testing are greatly facilitated. This model is particularly valuable for investigating the molecular mechanisms of ALA dehydratase deficiency porphyria, lead-induced porphyria, and heme-dependent signaling pathways in cancer biology. For additional details and custom requests, please contact Ascent Research.
